Completed PHASE4 INTERVENTIONAL 2-arm NCT01028287

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) (ACTH-NRDN)

Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study

Sponsor: Mallinckrodt

Conditions Diabetic Nephropathy Nephrotic Syndrome

Interventions ACTH

Updated 6 times since 2017 Last updated: May 30, 2013 Started: May 31, 2009 Primary completion: Dec 31, 2010 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Diabetic Nephropathy and Nephrotic Syndrome, this trial is completed. The trial is conducted by Mallinckrodt and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mallinckrodt
Southeast Renal Research Institute

Data source: Southeast Renal Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chattanooga, United States